Amedisys (AMED) Earns Daily Media Sentiment Score of 0.14

News headlines about Amedisys (NASDAQ:AMED) have been trending somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amedisys earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the health services provider an impact score of 46.433702164666 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Shares of Amedisys stock opened at $61.43 on Friday. The stock has a market capitalization of $2,086.67, a P/E ratio of 69.81, a PEG ratio of 1.05 and a beta of 0.62. The company has a current ratio of 1.45, a quick ratio of 1.45 and a debt-to-equity ratio of 0.15. Amedisys has a 1 year low of $45.60 and a 1 year high of $65.91.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, February 27th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). The firm had revenue of $404.24 million for the quarter, compared to the consensus estimate of $394.96 million. Amedisys had a net margin of 1.98% and a return on equity of 15.14%. During the same quarter in the prior year, the firm posted $0.44 earnings per share. analysts predict that Amedisys will post 3 EPS for the current year.

A number of research analysts have recently commented on the company. BidaskClub upgraded Amedisys from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $57.00 price target for the company in a report on Tuesday, February 6th. TheStreet lowered Amedisys from a “b” rating to a “c+” rating in a report on Wednesday, February 28th. Robert W. Baird set a $66.00 price target on Amedisys and gave the stock a “hold” rating in a report on Thursday, March 1st. Finally, Oppenheimer upped their price target on Amedisys from $68.00 to $63.00 and gave the stock an “outperform” rating in a report on Thursday, March 1st. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Amedisys currently has an average rating of “Buy” and a consensus target price of $63.18.

COPYRIGHT VIOLATION WARNING: “Amedisys (AMED) Earns Daily Media Sentiment Score of 0.14” was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3298420/amedisys-amed-earns-daily-media-sentiment-score-of-0-14.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Harris  and FLIR Systems  Critical Comparison
Harris and FLIR Systems Critical Comparison
Brink’s  Releases FY18 Earnings Guidance
Brink’s Releases FY18 Earnings Guidance
Accelerate Diagnostics  versus Horiba  Critical Comparison
Accelerate Diagnostics versus Horiba Critical Comparison
Analysts Anticipate Radware  Will Post Earnings of $0.05 Per Share
Analysts Anticipate Radware Will Post Earnings of $0.05 Per Share
Zacks: Brokerages Expect Columbia Banking System, Inc.  Will Announce Quarterly Sales of $142.70 Million
Zacks: Brokerages Expect Columbia Banking System, Inc. Will Announce Quarterly Sales of $142.70 Million
Zacks: Analysts Expect Hydrogenics  Will Post Quarterly Sales of $10.20 Million
Zacks: Analysts Expect Hydrogenics Will Post Quarterly Sales of $10.20 Million


© 2006-2018 Ticker Report. Google+.